antigen receptor Articles
-
New Cell Contenders in the CAR Field (Part 1)
Chimeric antigen receptor T-cells (CAR-T) are one of the first clinically approved therapies to take full advantage of the most significant advancements in immunology and genetic engineering. The resulting therapeutics have been shown to produce remission rates exceeding 80% in patients with CD19+ B-cell lymphoma, making them nothing short of remarkable [1]. Unfortunately, CAR-T cells seem ...
By Indee Labs
-
The Limitations and Challenges of Cancer Therapies
Considerable investment into cancer research has led to the development of remarkable new therapies, which have greatly improved therapeutic outcome for the countless individuals diagnosed with cancer. Until recently, almost all therapies that were granted clinical approval were small molecules. However, biotechnological advances in the last several decades have made it possible to develop ...
By Indee Labs
-
The Problem with Gene-Modified Cell Therapy Manufacturing
Gene-modified cell therapies (GMCTs) represent the most effective therapeutic platform for many patients with advanced diseases including relapsed and refractory leukemia, non-Hodgkin lymphoma, and other blood cancers [1]. Specifically, chimeric antigen receptor T cell (CAR-T) therapies targeting CD19 have demonstrated remarkable responses and possibly cures in patients with advanced acute ...
By Indee Labs
-
Four Novel Drug Delivery Systems You Should Know
In the field of medicine, effectively delivering drugs to the target site in the body is crucial for successful treatment. Over the years, several innovative drug delivery systems have been developed to improve drug efficacy and patient outcomes. In this article, we will discuss four novel drug delivery systems that have shown promising results in recent research. These systems include ...
-
Celdara Medical Receives National Institutes of Health Funding to develop a new CAR T cell platform to treat solid tumors
Celdara Medical, LLC today announced that the National Cancer Institute of the National Institutes of Health (NIH) has awarded a Small Business Innovation Research (SBIR) Phase I award to fund the company’s proof of concept studies on a new platform to improve chimeric antigen receptor (CAR) T cells efficacy to treat solid tumors. Dr. Joana Murad-Mabaera, who leads this effort, stated, ...
-
The ins and outs of TCR-T cell therapy
Adoptive cell transfer (ACT) therapy is one of the most effective therapeutic options for tumor immunotherapy that is currently emerging in clusters. Chimeric antigen receptors (CARs) and engineered T cell receptors (TCRs) are the main adoptive immunotherapies in recent years. TCR-engineered T cells express tumor antigen-specific receptors with alpha and beta chains generated from high-quality, ...
-
Cytokines in CAR-T Cell Therapy
What is CAR T-cell therapy? Car-t cell therapy involves genetically engineering T cells isolated from patients or allogeneic donors to express chimeric antigen receptors (CAR) that specifically recognize and kill tumor cells. As a "living" drug, CAR-T therapy is very different from traditional drugs. It is a new type of precision targeted therapy for the treatment of tumors. Compared with ...
-
CAR-T Cell Anti-Cancer Therapy Ushered in A Revolutionary Breakthrough!
Chimeric antigen receptor T cells (CAR-T) and T cell antigen receptor chimeric T cells (TCR-T) are currently the "top stream" in adoptive T cell tumor immunotherapy. In particular, CAR-T therapy, which has been approved by the FDA, is rewriting the treatment paradigm of some hematological tumors. However, adoptive T cell therapy remains of little success in solid tumors. The main reason is that ...
-
Tumor Glycan-Targeted Therapy
Glycosylation is a sophisticated type of post-translational modification that impacts over 50% of cellular proteins and is a critical regulator of many eukaryotic processes. Aberrant glycosylation is a common hallmark of many malignancies and is important at all stages of tumor growth. Glycosylation regulates a range of physiopathological processes, including cell-cell adhesion, cell-matrix ...
-
Effect of interferon receptor pathway on CAR-T cell-mediated killing of solid tumors
Researchers at Massachusetts General Hospital (MGH) have found that interferon gamma receptor (IFNgR) signaling is essential for the susceptibility of CAR-T cell immunotherapy to kill malignant gliomas. The same phenomenon has been observed in other solid tumors. The findings may partially explain why liquid and solid tumors respond very differently to CAR-T cell therapy. Chimeric antigen ...
-
Injecting mRNA and generating CAR-T directly in the body to repair the heart in one shot
January 6, 2022—Researchers at the Perelman School of Medicine at the University of Pennsylvania published a research paper in Science titled: CAR-T cells produced in vivo to treat cardiac injury. Heart damage or inflammation can induce fibroblasts to overproduce fibrous material, causing cardiac fibrosis, which hardens the heart muscle and impairs heart function. Heart failure, liver ...
-
Gamma delta T cells in tumor immunotherapy
Immunotherapy, in addition to surgery, chemotherapy, and radiotherapy, has now become the fourth pillar of anticancer treatment, with T cell-based immunotherapy being a successful cancer treatment technique. T cells can be separated into two subpopulations based on the expression of T-cell receptors (TCRs). αβ T cells, expressing expressing αβ TCR, recognize peptide antigens, such as those ...
-
A Novel Potential Target for CAR-T Cell Therapy in Human Solid Tumors Discovered
At present, chimeric antigen receptor T cell therapy (CAR-T) has made significant achievements in the treatment of specific hematological cancers, allowing patients with relapsed/refractory disease to survive longer and become healthier, but in clinical studies, cell therapy has actually not been successful in the treatment of patients with solid tumors, in part due to the lack of tumor targets ...
-
Cancer Target: Mesothelin
Mesothelin is a glycosylphosphatidylinositol (GPI)-anchored cell surface glycoprotein. Its biological function has not yet been clarified, but due to its limited distribution in normal tissues and high expression in some tumor tissues, it is expected to be used in tumor-specific treatment. In existing studies of human epidermoid carcinoma cell lines expressing mesothelin, biodistribution analysis ...
-
Targeted Therapy of Intracellular Oncoproteins by Peptide-centered CAR T Cells
Researchers at the Children's Hospital of Philadelphia (CHOP) have made a breakthrough in the treatment of aggressive solid cancers, and they have developed a new cancer treatment that targets proteins within tumor cells that are essential for tumor growth and survival, but this has not been possible before. Using the power of large data and advanced computational methods, researchers can ...
-
Immune Strategies for Cancer Treatment
In the search for innovative and effective ways to target cancer, we are faced with more than just a challenging problem; we are faced with our own cells as opponents. Cancer cells evolve to achieve an optimum of physical fitness, giving them an array of abilities that no cell should possess in a healthy organism. One way to find novel therapies against cancer therefore could imply finding a ...
-
Four Chromatographic Separation Techniques
The Basic Principles of Chromatography When the components in the mixture of solutions are moved forward in the mobile phase by the material moving the sample, these components pass through the stationary phase. The difference in size and strength of each component causes the difference in the residence time of the component to flow out of the stationary phase. Types of Chromatography According ...
-
What are the ADC drugs?
Antibody-drug conjugates (ADCs) continue to rise at home and abroad, but ADCs are not a new thing. Why has ADC been surging for so many years? What kind of magic power it contains, and what makes its growth path so tortuous? Let's take a brief look at the magical "magic bullet"-ADC. ADC (antibody-conjugated drug) is not a new concept. As early as the early 20th century, the Nobel Prize winner ...
By BOC Sciences
-
Antibody Drug Conjugates: "Biological Missiles" For Targeting Cancer Therapy
Antibody-drug conjugates (ADCs) usually consist of monoclonal antibodies (mAbs) covalently linked to cytotoxic drugs via chemical linkers. With high specific targeting ability and strong killing effect, it has achieved precise and efficient removal of cancer cells, and has become one of the hot spots in the development of anticancer drugs. In 2000, the FDA first approved the ADC drug Mylotarg ...
-
Natural killer cell reprogramming with chimeric immune receptors
Abstract Natural killer (NK) cells are emerging as a new tool for cell therapy of cancer. However, some cancer subtypes are relatively resistant to NK cell cytotoxicity. Expression of anti-CD19 chimeric signaling receptors can enhance NK-cell reactivity against CD19+ leukemia and lymphoma cells. Here we describe a method to enforce expression of such receptors in human NK cells relying on ...
By Nkarta, Inc.
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you